Savara Inc Proceeds from Lines of Credit
Savara Inc (SVRA) reported Proceeds from Lines of Credit of $9.37 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2020-03-12
- Savara Inc proceeds from lines of credit for the quarter ending 2017-12-31 was -$3.57M.
- Savara Inc proceeds from lines of credit for the quarter ending 2017-09-30 was $0.00.
- Savara Inc proceeds from lines of credit for the quarter ending 2015-12-31 was $0.00.
- Savara Inc proceeds from lines of credit for fiscal 2018 was $9.37M, a 17.32% decline from fiscal 2017.
- Savara Inc proceeds from lines of credit for fiscal 2017 was $11.33M.
- Savara Inc proceeds from lines of credit for fiscal 2015 was $15.00M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month | Proceeds from Lines of Credit 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $9.37M 10-K · filed 2020-03-12 | ||||
| 2017-12-31 | -$3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$3.57M derived: sum of 2 quarters · filed 2019-03-13 | $11.33M 10-K · filed 2019-03-13 | $14.89M 10-K · filed 2018-03-14 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $14.89M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $14.89M 10-Q · filed 2018-08-09 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $15.00M 10-K · filed 2017-03-06 | |||
| 2015-09-30 | $15.00M 10-Q · filed 2016-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |